1Williams R, James OF, Wames TW, et al. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double - blind, randomized, dose - finding muhicentre study [J] . Eur J Gastroenterol Hepatol, 2010, 12 (2) : 203 -208.
2Romero- G6mez M, Jover M, Del Campo JA, et al. Variations in the promoter region of the glutamines gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study [J]. Ann In- ter Med, 2010, 153 (5) : 281 -288.
3Shawcross DL, Sharifi Y, Canavan JB, et al. Infection and systemic inflammation, not ammonia, are associated with grade3/4 hepatic en- cephalopathy, but not mortality in cirrhosis [J].J Hepatol, 2011, 54 (4) : 640 - 645.
5Mendez M, Mendez - Lopez M, Lopez L, et al. Acetyl cholinesterase activity in an experimental rat model of type C hepatic encephalopathy [J].Acta Histoehem, 2011, 113 (3) : 358 -362.
